GleamWall
中文EN

NUS NU SKIN ENTERPRISES, INC.

Wholesale-Drugs, Proprietaries & Druggists' Sundries · NYSE · SEC CIK 1021561 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-15.3%
TTM net income YoY-313.7%
TTM EPS YoY-321.9%
Revenue 3-yr CAGR-12.9%
Net income 3-yr CAGR—

Margins

Gross margin67.8%
Operating margin-2.0%
Net margin-17.7%
FCF margin-2.0%
EBITDA margin1.8%

Returns

ROE-34.8%
ROA-18.6%
ROIC (approx.)-3.1%
Asset turnover1.05x

Leverage & solvency

Liabilities / assets49.7%
Debt / equity0.37x
Current ratio2.04x
Interest coverage-1.79x

Cash quality & payout

Operating cash flow / net income-0.06x
Accruals ratio-19.9%
Payout ratio—
Capex / revenue3.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$1.49B$1.73B
Cost of revenue$453.76M$550.23M
Gross profit$1.03B$1.18B
R&D expense$10.80M$13.00M
SG&A expense$432.14M$479.04M
Operating income$65.76M-$151.59M
Interest expense$13.95M$26.41M
Pretax income$196.20M-$175.05M
Income tax$35.99M-$28.46M
Net income$160.20M-$146.59M
EBITDA$118.02M-$81.78M
EPS (basic)3.25-2.95
EPS (diluted)3.18-2.95
Weighted avg. shares (diluted)50.30M49.66M
Balance sheet
Cash & equivalents$238.63M$186.88M
Short-term investments$1.21M$11.11M
Receivables$39.54M$50.78M
Inventory$178.64M$190.24M
Current assets$547.70M$538.60M
PP&E, net$377.17M$379.60M
Goodwill$83.62M$83.62M
Intangibles$42.61M$74.28M
Total assets$1.41B$1.47B
Current liabilities$263.73M$296.61M
Short-term debt$20.00M$30.00M
Long-term debt$204.19M$363.61M
Total debt$224.19M$393.61M
Total liabilities$600.07M$817.46M
Shareholders' equity$805.24M$651.46M
Net debt-$14.44M$206.73M
Cash flow statement
Operating cash flow$80.29M$111.74M
Capital expenditure$34.28M$41.58M
Free cash flow$46.01M$70.16M
Investing cash flow$170.66M-$37.96M
Financing cash flow-$202.40M-$133.18M
Depreciation & amortization$52.26M$69.81M
Stock-based compensation$24.11M$14.82M
Dividends paid$11.83M$11.93M
Share buybacks$20.04M$0

Free plan shows the latest 2 periods; Pro shows all 18 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.